Fusen Pharmaceutical Company Limited (HKG:1652)

HKG:1652 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	87.84	83.84	21.06	34.85	128.11	81.06
Short-Term Investments	-	-	-	-	-	0.64
Cash & Short-Term Investments	87.84	83.84	21.06	34.85	128.11	81.71
Cash Growth	15.59%	298.19%	-39.58%	-72.80%	56.79%	-73.86%
Accounts Receivable	119.11	121.96	113.88	183.48	247.19	157.58
Other Receivables	71.19	82.38	121.87	114.15	66.85	103.61
Receivables	190.3	204.34	235.75	297.63	314.04	261.19
Inventory	191.26	192.82	174.72	184.2	123.49	128.97
Prepaid Expenses	-	-	-	5.49	-	-
Other Current Assets	15.27	13.7	28.09	44.63	48.43	37.35
Total Current Assets	484.66	494.69	459.61	566.8	614.06	509.22
Property, Plant & Equipment	538.53	550.37	621.33	562.18	529.75	506.03
Long-Term Investments	59.59	58.92	43.88	148.97	178.31	198.06
Other Intangible Assets	28.02	28.03	28.14	22.55	0.48	0.68
Long-Term Deferred Tax Assets	2.38	2.48	6.64	5.02	5.08	5.63
Other Long-Term Assets	128.38	128.94	78.57	38.22	22.6	19.7
Total Assets	1,242	1,263	1,238	1,344	1,350	1,239

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	131.07	148.16	123.47	167.55	163.61	102.12
Accrued Expenses	431.38	200.4	160.84	147.32	157.57	143.76
Short-Term Debt	-	4.61	4.61	4.61	230.45	150.52
Current Portion of Long-Term Debt	306.53	293.28	303.54	236.56	-	20
Current Portion of Leases	0.49	0.46	0.92	1.09	2.11	1.83
Current Income Taxes Payable	5.12	5.12	5.51	6.09	7.15	-
Current Unearned Revenue	1.63	2.68	10.57	3.9	67.55	4.62
Other Current Liabilities	-	221.95	164.63	97.43	93.65	66.42
Total Current Liabilities	876.21	876.65	774.07	664.52	722.08	489.27
Long-Term Debt	7	7	79.1	105.7	-	76
Long-Term Leases	-	0.49	0.13	0.77	0.43	1.94
Long-Term Unearned Revenue	14.06	21.37	16.5	10.23	11.32	10.51
Long-Term Deferred Tax Liabilities	-	-	-	0.3	3.54	4.68
Total Liabilities	897.27	905.51	869.8	781.52	737.38	582.39

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	6.18	6.18	6.18	6.31	6.38	6.48
Additional Paid-In Capital	-	224.23	224.23	230.78	246.73	259.46
Retained Earnings	-	95.45	103.82	292.61	328.88	363.49
Treasury Stock	-	-	-	-0.08	-0.05	-0.04
Comprehensive Income & Other	339.43	33.39	35.44	33.91	32.22	28.79
Total Common Equity	345.61	359.25	369.67	563.52	614.17	658.17
Minority Interest	-1.33	-1.33	-1.31	-1.29	-1.27	-1.23
Shareholders' Equity	344.28	357.92	368.36	562.23	612.89	656.94
Total Liabilities & Equity	1,242	1,263	1,238	1,344	1,350	1,239

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	314.02	305.84	388.3	348.72	232.99	250.29
Net Cash (Debt)	-226.18	-221.99	-367.24	-313.87	-104.88	-168.59
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.31	-0.30	-0.50	-0.42	-0.14	-0.22
Filing Date Shares Outstanding	739.3	739.3	739.3	745.04	758.21	764.82
Total Common Shares Outstanding	739.3	739.3	739.3	745.04	758.21	764.82
Working Capital	-391.55	-381.95	-314.46	-97.72	-108.03	19.96
Book Value Per Share	0.47	0.49	0.50	0.76	0.81	0.86
Tangible Book Value	317.59	331.22	341.54	540.97	613.68	657.49
Tangible Book Value Per Share	0.43	0.45	0.46	0.73	0.81	0.86
Buildings	-	297.8	294.82	278.2	278.02	220.23
Machinery	-	193.54	246.2	204.33	144.85	142.73
Construction In Progress	-	28.28	21.93	3.46	0.58	4.79

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 20, 2026

Data Sources Report a data error